(eg, increased transmission and timing of viral clearance [32, 33] ) as key for emergence of these strains [15, 27] .
Reported GII.4 2015 viruses differ from GII.4 2012 in the amino acid sequences that encode GII.4 evolving blockade antibody epitopes A and D [15, 27] . Direct testing of the effect of these sequence changes on viral antigenicity has not been reported. Epitope A is an immunodominant antigenic site. Historically, changes in epitope A at positions 294, 368, 372, and 373 correlate with loss of blockade antibody binding and emergence of new epidemiologically significant GII.4 strains [7, 8, 34, 35] . Evolving blockade antibody epitope D (residues 391 and 393-395) includes the histo-blood group antigen (HBGA) carbohydrate-binding site 2 [11, 12] . These amino acids form weak interactions with saccharide side chains distal to the L-fucose bound in the conserved carbohydrate binding site 1 [36] . Residue substitutions within epitope D have a dual effect of modulating blockade antibody potency and ligand binding through stabilizing interactions. Historically, change at residue 393 in GII.4 virus-like particles (VLPs) resulted in loss of binding of a human monoclonal antibody (mAb) [7, 34] and modulation of Lewis and B antigen binding [9, 37] . Further, substitution at residue 395 also affected binding to H type 3, Lewis, A, and B antigens [9, 37, 38] . These data illustrate that single amino acid substitutions at key residues in functional domains can have significant phenotypic influences on GII.4 strains. In this study, we compared the antigenic and ligand-binding characteristics of GII.4 2012 and GII.4 2015 and found that evolution in blockade antibody epitopes in GII.4 2015 resulted in virus with antigenicity and ligand-binding properties that were significantly distinct from those for GII.4 2012, potentially accounting for the endemic spread of GII.4 2015.
MATERIALS AND METHODS

VLPs
Norovirus ORF2 sequences were synthesized by Bio Basic (Amherst, NY), and VLPs were expressed in baby hamster kidney cells, using Venezuelan equine encephalitis virus replicons expressing norovirus ORF2, as described previously [7] . Particle integrity was confirmed by visualization of particles approximately 40 nm in diameter, using electron microscopy.
mAb Development mAbs were developed by Genscript, using the MonoExpress protocol and GII.4.2012 VLP as immunogen. Seven mAbs were double subcloned and purified, each from a different single fused cell. mAbs were isotyped using the Pierce Rapid Isotyping Kit-Mouse (Thermo Scientific), following the manufacturer's directions.
Enzyme Immunoassay (EIA) and Blockade of VLP-Ligand Binding Assays
EIA and blockade antibody assays were performed at 37 • C. VLPs were used at a concentration of 0.25 µg/mL [39, 40] . Mean half maximal effective concentrations (EC 50 titers) and 95% confidence intervals (CIs) were determined from dose-response sigmoidal curve fits, using GraphPad 7.02 [41, 42] . An OD 450 >3 times the background value, after background subtraction, was scored as a positive EIA result. Samples with values below this limit or that did not block at least 50% of VLP binding to pig gastric mucin type III (PGM; Sigma Aldrich, St. Louis) at the lowest serum dilution tested were assigned a titer of >8 (EIA) or 0.5 times the limit of detection (blockade), for statistical analysis.
VLP-Ligand Binding Assays
VLP binding to PGM was detected by rabbit polyclonal antiserum to GII.4 2012 (Cocalico Biologicals, Stevens, PA), as described elsewhere [40] . Biotinylated HBGAs (10 µg/mL; Glycotech, Gaithersberg, MD) were bound to NeutrAvidincoated plates (ThermoFisher) for 1 hour before the addition of VLP (2 µg/mL) for 1 hour [7, 9] . Biotinylated HBGA-bound VLPs were detected as described for antibody blockade of ligand binding. Incubations were done at 37°C.
Ethics Statement
Thirty-five archived human sera samples estimated to have been collected during 2014-2016 and 14 sera collected from healthy human adult volunteers in 2016 who provided samples according to established institutional review board guidelines after informed consent were used in this study. Additional data on donor demographic characteristics are unavailable. Before use, sera were heat inactivated for 30 minutes at 56 • C. Experimentation guidelines of the Department of Health and Human Services were followed. Statistical analyses were performed using GraphPad Prism 7.02 [7, 41] Figure 7B ), as previously reported for GII.4 strains [9] . GII.4 2015 uniquely bound to Lewis x. Lewis x binding was confirmed to be dose dependent ( Figure 7C ). These data support residue 393 as a key modulator of carbohydrate binding and demonstrate the effect of a single residue substitution on ligand-binding preferences and potentially susceptible host populations.
RESULTS
Changes
DISCUSSION
Mechanisms of the emergence of pandemic GII.4 human norovirus include antigenic drift (ie, evolution in specific epitopes) [7, 43] , recombination between polymerase and capsid sequences from different strains [14] , expanded host range (ie, broad binding of HBGAs types) [9, 44] , and increased symptoms/extended duration of shedding relative to other genotypes [45, 46] . By comparing the capsid features of GII.4 2012 and GII.4 2015, we demonstrated that antigenic drift is a major driving force for new GII.4 strains even during periods of endemic (subpandemic) levels of disease. The question of how much change is needed between strains to generate a new dominant variant is just beginning to be explored. The threshold is dependent on the position of the changed residue [7, 47] . How the number of residue changes and the order of these changes affect viral fitness are unknown. Yet, this information is vital to our ability to develop effective surveillance approaches that could influence public health outcomes through behavior changes that could mitigate disease spread or through vaccination programs in which strain reformulation may be needed. Substitutions in epitope A are associated with pandemic strain emergence [7, 47] . Eight known residues of epitope A have been identified, with 4 footprints for antibody binding: linear 294-298 anchor, 368 anchor, 373 anchor, and a rare group of antibodies that have some cross-reactivity with other GII.4 strains but are still dependent on epitope A residues for binding [8, 34, 35] . Here, the GII.4 2015 R373H substitution results in loss of blockade for the 3 mAbs that anchor at 373. Of note, E368 is conserved between GII.4 2012 and GII.4 2015, yet the 2 mAbs that anchor at 368 were reduced in potency by 5-fold. 368 and 373 are on opposite sides of epitope A, making it unlikely that the R373H change in epitope A is accounting for the decrease in 368 anchor mAbs. Modeling of the polar interactions identified 2 bonds between E368 and either T350, found in GII.4 2012, or I350, found in GII.4 2015. The exchange of the larger hydrophilic threonine for the smaller, more hydrophobic isoleucine may be affecting the conformation of E368 presentation for antibody binding, thus reducing antibody affinity for epitope A mAbs that anchor at E368. If true, then 350 is another example of a residue outside an epitope that can regulate antibody blockade potency, likely by regulating local epitope conformation [40] . Awareness of how and which residues outside antibody epitopes may influence antibody neutralization will be an important component in developing sophisticated surveillance systems able to detect prepandemic strain changes.
GII.4 2015 viruses restored epitope D (393-395) to STT and subsequently restored blockade potency of the human mAb to epitope D. Affinity for different HBGAs is mediated by residues of epitope D [9, 38] . Here, G393S translated to improved binding to the biologically relevant carbohydrates in PGM and synthetic Lewis x. It is not known whether altered carbohydrate preference coupled with the loss of 373 mAbs is enough to expand the virus into new populations in the context of high herd immunity. At the population level, these changes decreased sera blockade potency by 32%. In comparison, blockade antibody titer in convalescent serum from people infected with GII.4 2009 lost approximately 70% of the blockade titer for GII.4 2012 [34] .
The primary limitation of this study is the lack of ability to test the effects of specific residue changes on virus binding, entry, and neutralization. It is also important to note that the sequences studied here are representative strains. In a pandemic environment, a strain exists as a quasi-species with some variation in sequence [27] . For example, GII.4 2012 strains with G393 and S393 cocirculate. It is possible that cocirculation of strains with varied ligand-binding preferences may serve to expand the susceptible host pool at the genetic level. Furthermore, viruses within the quasi-species will escape antibody-mediated protection and spread, be attenuated by low-titer cross-reactive antibodies, or be neutralized and become extinct. The strains in the middle between escape and extinction may extend herd immunity by boosting cross-reactive antibodies to slightly altered epitopes, possibly extending the life-span of either natural or vaccine-induced immunity.
Like other RNA viruses, including influenza A virus and human immunodeficiency virus [48, 49] , recombinant noroviruses contribute to global disease burden [15] . The role of human norovirus RNA polymerases in strain dominance is not clear, and replication models are needed to determine the effect of polymerase activity on viral fitness. Early studies suggested that GII.4 polymerases had higher mutation rates, potentially explaining high evolution rates [50] . At this time, it is uncertain whether any of the other human norovirus RNA polymerases have altered fidelity rates as compared to the early GII.4 strains. Nor is it clear whether human norovirus polymerases encode any virulence determinants or are the target for strong T-cell responses. Further investigation of the role of polymerases are warranted, but this study clearly demonstrates that GII.4 Sydney strains are undergoing significant antigenic and ligand-binding change over time, providing direct evidence for the dominance of the GII.4 2015 strains as compared to GII.4 2012. These data support the fundamental role of viral evolution of the capsid gene in norovirus emergence and persistence. Time will reveal whether the GII.P16/GII.2012 capsid strain is a final variant of the GII.4 Sydney viruses as herd immunity drives them toward extinction or whether continued evolution at residue 368 could play an important role and eliminate a second class of epitope A blockade antibodies, potentially negating herd immunity and initiating a new norovirus pandemic.
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